Approval
FDA clears Abbisko's pimicotinib, sold by Merck KGaA, for tenosynovial giant cell tumor
US regulators approved PIMJETMI, a once-a-day oral CSF-1R inhibitor, for adults with symptomatic TGCT where an operation could leave them worse off. In the phase 3 MANEUVER study, 56% responded by week 25 compared with 3% on placebo. The label carries liver-injury warnings and requires blood-test monitoring; Merck KGaA holds global marketing rights.
Written by Gosset from public sources. Source types: Press release · SEC/exchange filing. Sources are available to Gosset users. Log in to see them.